|
Q |
Aia1 |
Adjuvant induced arthritis QTL 1 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
|
|
Q |
Aia2 |
Adjuvant induced arthritis QTL 2 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr 4:40,471,453...75,939,996
|
|
Q |
Aia3 |
Adjuvant induced arthritis QTL 3 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr 4:75,939,858...140,508,796
|
|
Q |
Aia4 |
Adjuvant induced arthritis QTL 4 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr15:62,440,892...97,773,284
|
|
Q |
Bw1 |
Body weight QTL1 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 2:44,904,355...85,286,097
|
|
Q |
Bw19 |
Body weight QTL 19 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 7:1,669,658...46,669,658
|
|
Q |
Bw2 |
Body weight QTL2 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 4:1...45,429,897
|
|
Q |
Bw3 |
Body weight QTL3 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 8:61,019,838...121,662,124
|
|
Q |
Bw4 |
Body weight QTL4 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 9:5,346,479...50,346,479
|
|
Q |
Bw5 |
Body weight QTL5 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr14:11,334,906...30,674,469
|
|
Q |
Bw60 |
Body weight QTL60 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr14:84,164,970...100,078,267
|
|
Q |
Bw61 |
Body weight QTL61 |
|
IEA |
|
RGD |
PMID:11853145 |
RGD:619672 |
NCBI chr 1:182,535,316...227,535,316
|
|
Q |
Cari1 |
Carrageenan-induced inflammation QTL 1 |
|
IEA |
|
RGD |
PMID:10087293 |
RGD:69693 |
NCBI chr10:54,296,227...107,713,808
|
|
Q |
Cari2 |
Carrageenan-induced inflammation QTL 2 |
|
IEA |
|
RGD |
PMID:10087293 |
RGD:69693 |
NCBI chr 2:143,746,578...205,135,428
|
|
Q |
Ciaa2 |
CIA Autoantibody QTL 2 |
|
IEA |
|
RGD |
PMID:10857786 |
RGD:61066 |
NCBI chr10:63,719,161...107,713,808
|
|
Q |
Eau1 |
Experimental allergic uveoretinitis QTL 1 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr 4:26,234,499...134,199,155
|
|
Q |
Eau2 |
Experimental allergic uveoretinitis QTL 2 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr12:1...33,700,600
|
|
Q |
Eau3 |
Experimental allergic uveoretinitis QTL 3 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr10:18,035,782...63,035,782
|
|
Q |
Hcar13 |
Hepatocarcinoma resistance QTL 13 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 4:1...33,538,816
|
|
Q |
Hcar14 |
Hepatocarcinoma resistance QTL 14 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr18:57,825,243...85,493,247
|
|
Q |
Hcar4 |
Hepatocarcinoma resistance QTL 4 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 1:202,851,915...223,964,440
|
|
Q |
Hcar5 |
Hepatocarcinoma resistance QTL 5 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 1:223,964,326...236,074,012
|
|
Q |
Hcar6 |
Hepatocarcinoma resistance QTL 6 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
|
|
Q |
Hcar7 |
Hepatocarcinoma resistance QTL 7 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 4:61,041,057...94,638,356
|
|
Q |
Hcar8 |
Hepatocarcinoma resistance QTL 8 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 4:124,700,988...169,700,988
|
|
Q |
Hcas5 |
Hepatocarcinoma susceptibility QTL 5 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 1:185,857,683...270,518,180
|
|
Q |
Hcas6 |
Hepatocarcinoma susceptibility QTL 6 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr14:39,411,170...87,582,095
|
|
Q |
Hcas7 |
Hepatocarcinoma susceptibility QTL 7 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr15:2,315,759...53,331,089
|
|
Q |
Iddm3 |
Insulin dependent diabetes mellitus QTL 3 |
|
IEA |
|
RGD |
PMID:10441739 |
RGD:61481 |
NCBI chr 2:192,287,802...237,287,802
|
|
Q |
Insul2 |
Insulin level QTL 2 |
|
IEA |
|
RGD |
PMID:9819774 |
RGD:69703 |
NCBI chr20:1...6,693,431
|
|
Q |
Lnnr1 |
Liver neoplastic nodule remodeling QTL 1 |
|
IEA |
|
RGD |
PMID:12672032 |
RGD:629574 |
NCBI chr 7:36,178,764...81,178,764
|
|
Q |
Lnnr2 |
Liver neoplastic nodule remodeling QTL 2 |
|
IEA |
|
RGD |
PMID:12672032 |
RGD:629574 |
NCBI chr 1:243,953,669...270,518,180
|
|
Q |
Lnnr3 |
Liver neoplastic nodule remodeling QTL 3 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 2:1...42,977,529
|
|
Q |
Lnnr4 |
Liver neoplastic nodule remodeling QTL 4 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:1...34,785,618
|
|
Q |
Lnnr5 |
Liver neoplastic nodule remodeling QTL 5 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:62,424,592...88,113,509
|
|
Q |
Lnnr6 |
Liver neoplastic nodule remodeling QTL 6 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:65,613,454...109,350,286
|
|
Q |
Niddm1 |
Non-insulin dependent diabetes mellitus QTL 1 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 1:228,180,243...255,849,249
|
|
Q |
Niddm14 |
Non-insulin dependent diabetes mellitus QTL 14 |
|
IEA |
|
RGD |
PMID:9585427 |
RGD:61072 |
|
|
Q |
Niddm15 |
Non-insulin dependent diabetes mellitus QTL 15 |
|
IEA |
|
RGD |
PMID:9585427 |
RGD:61072 |
NCBI chr14:1...11,334,906
|
|
Q |
Niddm2 |
Non-insulin dependent diabetes mellitus QTL 2 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 2:147,287,892...192,287,892
|
|
Q |
Niddm3 |
Non-insulin dependent diabetes mellitus QTL 3 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr10:61,843,633...83,061,236
|
|
Q |
Niddm37 |
Non-insulin dependent diabetes mellitus QTL 37 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr14:11,334,716...100,078,267
|
|
Q |
Niddm38 |
Non-insulin dependent diabetes mellitus QTL 38 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr19:10,329,076...74,246,245
|
|
Q |
Niddm39 |
Non-insulin dependent diabetes mellitus QTL 39 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr 3:70,311,536...115,311,536
|
|
Q |
Niddm40 |
Non-insulin dependent diabetes mellitus QTL 40 |
|
IEA |
|
RGD |
PMID:10902185 |
RGD:619671 |
NCBI chr 1:140,833,106...185,833,106
|
|
Q |
Niddm41 |
Non-insulin dependent diabetes mellitus QTL 41 |
|
IEA |
|
RGD |
PMID:10902185 |
RGD:619671 |
NCBI chr17:1...38,037,084
|
|
Q |
Scl29 |
Serum cholesterol level QTL 29 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
|
|
Q |
Scwia1 |
Streptococcal cell wall induced arthritis QTL 1 |
|
IEA |
|
RGD |
PMID:10331011 |
RGD:61064 |
NCBI chr 4:75,939,858...140,508,796
|
|
Q |
Slep1 |
Serum leptin concentration QTL 1 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 2:44,904,355...89,904,355
|
|
Q |
Slep2 |
Serum leptin concentration QTL 2 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 6:22,288,257...67,288,257
|
|
Q |
Stl10 |
Serum triglyceride level QTL 10 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 4:22,288,453...45,429,897
|
|
Q |
Stl11 |
Serum triglyceride level QTL 11 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 7:121,393,075...137,014,596
|
|
Q |
Stl12 |
Serum triglyceride level QTL 12 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
|
|
Q |
Tls1 |
T-lymphoma susceptibility QTL 1 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
|
|
Q |
Tls2 |
T-lymphoma susceptibility QTL 2 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
NCBI chr 7:82,111,382...132,099,989
|
|
Q |
Tls3 |
T-lymphoma susceptibility QTL 3 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
NCBI chr10:27,587,226...96,099,902
|
|